Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 22 of 37, showing 5 Applications out of 181 total, starting on record 106, ending on 110

# Protocol No Study Title Investigator(s) & Site(s)

106.

ECCT/21/02/01   PTSD 102 TONIX
    A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants with PTSD Taken Daily at Bedtime (Protocol No. TNX-CY-P308).   
Principal Investigator(s)
1. Prof. Lukoye Atwoli
Site(s) in Kenya
1. Moi Teaching and Referral Hospital/Moi University (Uasin Gishu county)
2. KEMRI Nairobi (Nairobi City county)
3. Aga Khan University Hospital (Nairobi City county)
 
View

107.

ECCT/15/12/02   The Evidence for Contraceptive options and HIV Outcomes (ECHO) Trial
    A Multi Centre, Open label, Randomized Clinical Trial, Comparing HIV incidence and Contraceptive Benefits in Women using Depot Medroxyprogesterone Acetate, Levernogestrel (LNG) implant and Copper Intrauterine Devices (IUD).   Short Title : The Evidence for Contraceptive options and HIV Outcomes (ECHO) Trial   
Principal Investigator(s)
1. Prof Elizabeth Anne Bukusi
Site(s) in Kenya
KEMRI-RCTP Study center , Lumumba
 
View

108.

ECCT/21/09/04   Recombinant COVID-19 Vaccine
    A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells) for the prevention of COVID-19 in adults aged 18 years and older            
Principal Investigator(s)
1. Sylvester Kimaiyo
Site(s) in Kenya
1. KAVI-Institute of Clinical Research (Nairobi City county)
2. Moi Teaching and Referral Hospital (Uasin Gishu county)
3. Kenya Medical Research Institute, Kilifi (Kilifi county)
 
View

109.

ECCT/15/12/05   Post-discharge Malaria Chemoprevention(PMC) study
    Malaria Chemoprevention with monthly treatment with dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: A 3-year, multi-centre, parallel-group, two-arm randomised placebo controlled superiority trial   
Principal Investigator(s)
1. Titus Kwambai
2. Simon Kariuki
Site(s) in Kenya
1. Siaya County Referral Hospital (Siaya county)
2. Homa Bay County Referral Hospital (Homa Bay county)
3. Migori County Referral Hospital (Migori county)
4. Busia County Referral Hospital (Busia county)
 
View

110.

ECCT/22/01/04   SKYSCRAPER 07
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE CANCERS HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY   
Principal Investigator(s)
1. Fredrick Chite Asirwa
2. Mansoor Saleh
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
View